Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target $481.67 +0.60 (+0.12%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$482.39 +0.72 (+0.15%) As of 10/17/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 28 Analyst RatingsSell1Hold3Buy24 Based on 28 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 1 has given a sell rating, 3 have given a hold rating, and 24 have given a buy rating for ALNY. Consensus Price Target $463.08-3.86% Downside According to the 28 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $463.08. The highest price target for ALNY is $583.00, while the lowest price target for ALNY is $310.00. The average price target represents a forecasted downside of -3.86% from the current price of $481.67. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALNY Analyst Ratings Over TimeTypeCurrent Forecast10/18/24 to 10/18/251 Month Ago9/18/24 to 9/18/253 Months Ago7/20/24 to 7/20/251 Year Ago10/19/23 to 10/18/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy24 Buy rating(s)24 Buy rating(s)21 Buy rating(s)18 Buy rating(s)Hold3 Hold rating(s)4 Hold rating(s)3 Hold rating(s)6 Hold rating(s)Sell1 Sell rating(s)0 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$463.08$433.04$346.13$286.82Forecasted Upside-3.86% Downside-4.23% Downside7.99% Upside-3.08% DownsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy ALNY Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ALNY Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Alnylam Pharmaceuticals Stock vs. The CompetitionTypeAlnylam PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.82 2.33 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside-3.86% Downside1,356.33% Upside13.60% UpsideNews Sentiment RatingPositive NewsSee Recent ALNY NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/17/2025Truist Financial3 of 5 starsDanielle Brill Not RatedBoost TargetBuy$459.00 ➝ $535.00+9.80%10/13/2025JPMorgan Chase & Co.2 of 5 starsJessica Fye Not RatedLower TargetOverweight$475.00 ➝ $473.00+3.03%10/10/2025HC Wainwright2 of 5 starsPatrick R. Trucchio Not RatedReiterated RatingBuy$570.00+24.74%10/8/2025Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingSell (D-)10/6/2025Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael UlzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$405.00 ➝ $475.00+4.55%10/6/2025Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPaul MatteisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$441.00 ➝ $495.00+8.47%9/19/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLuca IssiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$435.00 ➝ $500.00+10.58%9/17/2025Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTazeen AhmadSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$453.00 ➝ $520.00+12.46%9/16/2025The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSalveen RichterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$504.00 ➝ $566.00+22.67%9/11/2025Evercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLiisa BaykoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$280.00 ➝ $515.05+9.93% Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 9/5/2025BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKostas BiliourisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$450.00 ➝ $470.00+3.66%9/2/2025CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid LebovitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$527.00 ➝ $583.00+29.48%8/4/2025OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLeland GershellSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$490.00+21.95%8/4/2025Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndy ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeUnderperform ➝ Peer Perform8/1/2025ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGreg HarrisonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetSector Outperform$342.00 ➝ $450.00+12.00%8/1/2025UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$403.00 ➝ $550.00+38.02%8/1/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingWhitney IjemSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$390.00 ➝ $415.00+4.88%8/1/2025Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTiago FauthSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$333.00 ➝ $395.00-0.23%8/1/2025BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGena WangSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$329.00 ➝ $460.00+17.28%8/1/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEdward TenthoffSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$304.00 ➝ $449.00+14.47%8/1/2025Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKeay NakaeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$325.00 ➝ $400.00+1.98%7/31/2025Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph StringerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$377.00 ➝ $478.00+21.63%7/30/2025Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMartin AusterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$370.00+11.93%7/7/2025Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMaury RaycroftSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$328.00 ➝ $384.00+18.58%3/31/2025Redburn AtlanticSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoshua SmithSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$353.00+31.49%3/21/2025William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform1/7/2025Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOutperform$314.00 ➝ $310.00+31.53%10/21/2024TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$282.00 ➝ $371.00+25.37%10/11/2024Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingNeutral$220.00 ➝ $220.00-21.77%6/25/2024Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetMarket Perform$138.00 ➝ $159.00-33.15%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:48 AM ET. Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 17, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. Alnylam Pharmaceuticals Bull Case Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: The stock price has recently been set at approximately $456.35, indicating a strong market position and potential for growth. Equities research analysts have shown confidence in the company, with a recent price target increase to $495.00, suggesting an expected upside of over 8% from current levels. Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, reflecting positive sentiment and potential for future performance. The company has a significant market capitalization of around $59.82 billion, indicating stability and investor confidence in its long-term prospects. Recent institutional investments, such as KLP Kapitalforvaltning AS increasing its stake by 12.4%, demonstrate growing interest from major investors, which can be a positive signal for retail investors. Alnylam Pharmaceuticals Bear Case Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: The company has a high debt-to-equity ratio of 4.10, which may indicate financial risk and reliance on debt financing. Alnylam Pharmaceuticals, Inc. has a negative PE ratio of -184.76, suggesting that it is not currently profitable, which can be a concern for potential investors. Despite positive analyst ratings, the stock has experienced volatility, which may deter risk-averse investors. With a current ratio of 2.80, while it indicates good short-term financial health, it also suggests that the company may be holding excess inventory or cash that could be better utilized for growth. Market fluctuations and sector-specific challenges in the biopharmaceutical industry could impact the company's performance and stock price in the near term. ALNY Forecast - Frequently Asked Questions What is Alnylam Pharmaceuticals' forecast for 2025? According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $463.08, with a high forecast of $583.00 and a low forecast of $310.00. Should I buy or sell Alnylam Pharmaceuticals stock right now? 28 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There is currently 1 sell rating, 3 hold ratings and 24 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares. Does Alnylam Pharmaceuticals's stock price have much downside? According to analysts, Alnylam Pharmaceuticals's stock has a predicted downside of -3.86% based on their 12-month stock forecasts. Has Alnylam Pharmaceuticals been upgraded by Wall Street analysts recently? Over the previous 90 days, Alnylam Pharmaceuticals's stock had 2 upgrades by analysts. What analysts cover Alnylam Pharmaceuticals? Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Chardan Capital, Citigroup, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Scotiabank, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days. Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors? Analysts like Alnylam Pharmaceuticals more than other "medical" companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ALNY compares to other companies. Stock Forecasts and Research Tools Related Companies AMGN Stock Forecast GILD Stock Forecast VRTX Stock Forecast REGN Stock Forecast BIIB Stock Forecast UTHR Stock Forecast INCY Stock Forecast NBIX Stock Forecast IONS Stock Forecast EXAS Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:ALNY) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe Truth about AI Stocks’ Money MachineBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.